Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 8Neoplasms 4Recurrence 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hepatic Insufficiency 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Irinotecan 8Temozolomide 7FANG vaccine 4Topotecan 3Cyclophosphamide 3seclidemstat 2eribulin 2abemaciclib 2Pemetrexed 2Gemcitabine 2trifluridine tipiracil drug combination 1talazoparib 1surufatinib 1robatumumab 1regorafenib 1racotumomab 1palbociclib 1ganitumab 1figitumumab 1entrectinib 1dinutuximab 1copanlisib 1cixutumumab 1bempegaldesleukin 1Vincristine 1TB-403 1PM 01183 1PM 00104 1Nivolumab 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Ewing × copanlisib × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡